2024-09-24 - Analysis Report
## Abbott Laboratories (ABT) Stock Analysis Report

**Company Overview:** Abbott Laboratories is a multinational healthcare company that develops, manufactures, and sells a wide range of healthcare products, including pharmaceuticals, medical devices, diagnostics, and nutritionals.

**Performance Analysis:**

**1. Performance vs. S&P 500:**

* **Cumulative Return:**  ABT has returned 106.04%, while the S&P 500 (VOO) has returned 133.1%.
* **Relative Performance:**  This represents a -27.06% difference, placing ABT at the 15.01% percentile of its historical performance against the S&P 500.

**2. Recent Price Action:**

* **Closing Price:**  $114.81
* **5-day Moving Average:**  $114.90
* **20-day Moving Average:**  $114.81
* **60-day Moving Average:**  $109.29

**3. Technical Indicators:**

* **RSI:**  50.56, indicating a neutral market sentiment, neither overbought nor oversold.
* **PPO:**  -0.41, suggests a potential short-term downward trend.
* **Delta_Previous_Relative_Divergence:**  0.1 (-), indicating a recent slight decline in relative performance.
* **Expected_Return:**  69.85%, suggesting a potential maximum 5-year expected return on current investment.

**4. Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-07-31 | $0.74 | $10.38 B |
| 2024-05-02 | $0.70 | $9.96 B |
| 2023-11-01 | $0.82 | $10.14 B |
| 2023-08-03 | $0.79 | $9.98 B |
| 2024-07-31 | $0.79 | $9.98 B |

Abbott Laboratories' most recent earnings report for the quarter ending July 31, 2024, revealed a slight miss in earnings per share (EPS) compared to analyst expectations. Revenue, however, came in above expectations. This suggests a potential challenge in profitability despite strong revenue performance.

**5. Overall Analysis:**

Abbott Laboratories has exhibited a relatively stable performance over the past period, though its recent performance lags behind the S&P 500. Technical indicators suggest a neutral to slightly negative short-term outlook. While the recent earnings report showed some weakness in EPS, revenue exceeded expectations. The company's strong presence in the healthcare sector, combined with its diverse portfolio of products, indicates a potential for continued growth in the long term.

**6. Recommendations:**

Investors should carefully consider the current market environment and the company's long-term growth potential before making any investment decisions. While the recent earnings report revealed some weaknesses, the company's strong position in the healthcare industry suggests potential for future growth. Long-term investors may find Abbott Laboratories an attractive investment option, especially if they believe in the potential of the healthcare sector.
